Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. The company also develops enfortumab vedotin, which is in Phase 1 clinical trial for Nectin-4-positive solid tumors, including bladder cancer; and tisotumab vedotin that is in Phase II clinical trial for patients with cervical cancer and solid tumors. In addition, it conducts phase 3 clinical trials of ADCETRIS which includes ECHELON-1 for patients with newly diagnosed advanced stage classical Hodgkin lymphoma; ECHELON-2 for patients with newly diagnosed CD30-expressing MTCL; and the CHECKMATE 812 for patients with relapsed or refractory or transplant-ineligible, and advanced classical Hodgkin lymphoma. Further, the company's earlier stage clinical pipeline includes six other ADC programs consisting of ladiratuzumab vedotin, denintuzumab mafodotin, SGN-CD19B, SGN-CD123A, SGN-CD33A, and SGN-CD352A, as well as two immuno-oncology agents, including SEA-CD40 and SGN-2FF. It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:SGEN
CUSIP81257810
Phone425-527-4000
Debt
Debt-to-Equity RatioN/A
Current Ratio3.90
Quick Ratio3.51
Price-To-Earnings
Trailing P/E Ratio-84.60
Forward P/E Ratio-64.74
P/E GrowthN/A
Sales & Book Value
Annual Sales$482.25 million
Price / Sales24.51
Cash FlowN/A
Price / CashN/A
Book Value$4.71 per share
Price / Book15.81
Profitability
EPS (Most Recent Fiscal Year)($0.88)
Net Income$-125,530,000.00
Net Margins-7.75%
Return on Equity-21.01%
Return on Assets-17.56%
Miscellaneous
Employees1,100
Outstanding Shares158,790,000
Market Cap$11.64 billion
Seattle Genetics (NASDAQ:SGEN) Frequently Asked Questions
What is Seattle Genetics' stock symbol?
Seattle Genetics trades on the NASDAQ under the ticker symbol "SGEN."
How were Seattle Genetics' earnings last quarter?
Seattle Genetics, Inc. (NASDAQ:SGEN) issued its earnings results on Thursday, July, 26th. The biotechnology company reported $0.47 earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.34) by $0.81. The biotechnology company earned $170.20 million during the quarter, compared to analyst estimates of $141.07 million. Seattle Genetics had a negative return on equity of 21.01% and a negative net margin of 7.75%. Seattle Genetics's revenue was up 57.3% on a year-over-year basis. During the same period in the previous year, the company posted ($0.39) EPS. View Seattle Genetics' Earnings History.
When is Seattle Genetics' next earnings date?
What price target have analysts set for SGEN?
15 Wall Street analysts have issued 1 year price targets for Seattle Genetics' stock. Their predictions range from $50.00 to $98.00. On average, they anticipate Seattle Genetics' stock price to reach $70.6154 in the next twelve months. This suggests that the stock has a possible downside of 5.2%. View Analyst Price Targets for Seattle Genetics.
What is the consensus analysts' recommendation for Seattle Genetics?
15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seattle Genetics in the last year. There are currently 6 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Seattle Genetics.
What are Wall Street analysts saying about Seattle Genetics stock?
Here are some recent quotes from research analysts about Seattle Genetics stock:
- 1. JPMorgan Chase & Co. analysts commented, "With SGEN’s recent strength (up ~50% over the last 3 mos), we’ve been asked frequently – what would we need to see from Adcetris to maintain this momentum? In our view, this question should be more than adequately answered following a big beat this quarter with Adcetris sales coming in at $122.4M vs guidance of $105-110M and consensus of $107M. Additionally, management provided 3Q guidance of $130-135M vs cons of $115M. Coupled with continued pipeline progress (completion of enrollment in the pivotal cohort of EV-201 and first patient dosed in innovaTV 204/207, as previously disclosed), as well as narrowing of guidance for E-2 (now early 4Q18) we see this as another productive quarter on many fronts." (7/27/2018)
- 2. HC Wainwright analysts commented, "Valuation and risks. We reach a price target of $98 after adjusting new corporate tax rate, cash, and other program updates. The price target is based on a sum-of-parts NPV-DCF ($54.9 HL + $6.3 ALCL+ $14.1 PTCL + $20.3 platform + $2.8 cash). Key risks to achievement of our target price include trial failures, safety issues, regulatory delays, competition, and dilutive financing. Seattle Genetics Inc. July 27, 2018 H.C. WAINWRIGHT & CO. EQUITY RESEARCH 2Seattle Genetics, Inc." (7/27/2018)
- 3. According to Zacks Investment Research, "Seattle Genetics' sole marketed drug, Adcetris, is performing well since its launch. Moreover, its efforts to expand Adcetris’ label is encouraging. The label expansion in frontline Hodgkin lymphoma, pcALCL, CD30-expressing MF and T-cell lymphoma will boost sales. The company’s collaboration with Takeda for the global development and commercialization of Adcetris is encouraging. However, the company’s dependence on one product – Adcetris– for growth has its inherent risks. The recent label expansion of Merck’s Keytruda in the lymphoma indication is likely to increase competition. Though the company has multiple candidates in its pipeline, most of them are in early stages of development. Meanwhile, the company’s shares have outperformed the industry so far this year." (7/3/2018)
- 4. Cann analysts commented, "We have not included any sales or earnings from enfortumab vedotin by 2022 due to its stage of development, but we are encouraged by its development program, including data in the ASCO abstract and its having received Breakthrough Therapy Designation. Genetics’ approved drug for Hodgkin’s lymphoma, had sales of $307.6 million, or 63.8% of total revenue, in 2017. We estimate that Adcetris sales, including additional indications, CTCL and Anaplastic large cell lymphoma, and label expansion into frontline Hodgkin’s lymphoma, will increase to $766.7 million in 2022 and account for 70% of revenue. Continued strong data from ECHELON-1 are expected to drive adoption in the frontline Hodgkin’s setting." (5/17/2018)
Are investors shorting Seattle Genetics?
Seattle Genetics saw a drop in short interest in July. As of July 31st, there was short interest totalling 11,131,600 shares, a drop of 13.7% from the July 13th total of 12,901,751 shares. Based on an average daily volume of 1,075,590 shares, the days-to-cover ratio is currently 10.3 days. Approximately 7.1% of the shares of the company are sold short. View Seattle Genetics' Current Options Chain.
Who are some of Seattle Genetics' key competitors?
Some companies that are related to Seattle Genetics include NOVOZYMES A/S/S (NVZMY), Neurocrine Biosciences (NBIX), Qiagen (QGEN), bluebird bio (BLUE), AveXis (AVXS), BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), Aerie Pharmaceuticals (AERI), argenx (ARGX), Halozyme Therapeutics (HALO), Crispr Therapeutics (CRSP), Spark Therapeutics (ONCE), Acceleron Pharma (XLRN) and Regenxbio (RGNX).
Who are Seattle Genetics' key executives?
Seattle Genetics' management team includes the folowing people:
- Dr. Clay B. Siegall, Co-Founder, Chairman, Pres & CEO (Age 57)
- Mr. Todd E. Simpson, Chief Financial Officer (Age 57)
- Dr. Vaughn B. Himes, Chief Technology Officer (Age 57)
- Ms. Jean I. Liu, Gen. Counsel, Exec. VP of Legal Affairs & Corp. Sec. (Age 50)
- Dr. Jonathan G. Drachman, Strategic Advisor for Innovation (Age 56)
Has Seattle Genetics been receiving favorable news coverage?
Media headlines about SGEN stock have been trending somewhat positive this week, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Seattle Genetics earned a daily sentiment score of 0.02 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 48.34 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View Recent Headlines for Seattle Genetics.
Who are Seattle Genetics' major shareholders?
Seattle Genetics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Baker BROS. Advisors LP (32.15%), Baillie Gifford & Co. (8.99%), BlackRock Inc. (5.62%), Manning & Napier Group LLC (1.15%), FMR LLC (1.00%) and Point72 Asset Management L.P. (0.80%). Company insiders that own Seattle Genetics stock include Bros Advisors Lp Baker, Clay B Siegall, Darren S Cline, Eric Dobmeier, Felix Baker, Jonathan G Drachman, Marc E Lippman, Todd E Simpson and Vaughn B Himes. View Institutional Ownership Trends for Seattle Genetics.
Which institutional investors are selling Seattle Genetics stock?
SGEN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Manning & Napier Group LLC, Baillie Gifford & Co., Wasatch Advisors Inc., Nexthera Capital LP, Bank of America Corp DE, Pinnacle Associates Ltd. and Renaissance Technologies LLC. Company insiders that have sold Seattle Genetics company stock in the last year include Clay B Siegall, Darren S Cline, Eric Dobmeier, Jonathan G Drachman, Marc E Lippman, Todd E Simpson and Vaughn B Himes. View Insider Buying and Selling for Seattle Genetics.
Which institutional investors are buying Seattle Genetics stock?
SGEN stock was acquired by a variety of institutional investors in the last quarter, including Baker BROS. Advisors LP, Point72 Asset Management L.P., Eagle Asset Management Inc., BlackRock Inc., Carillon Tower Advisers Inc., First Trust Advisors LP, SG Americas Securities LLC and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have bought Seattle Genetics stock in the last two years include Bros Advisors Lp Baker and Felix Baker. View Insider Buying and Selling for Seattle Genetics.
How do I buy shares of Seattle Genetics?
Shares of SGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Seattle Genetics' stock price today?
One share of SGEN stock can currently be purchased for approximately $74.45.
How big of a company is Seattle Genetics?
Seattle Genetics has a market capitalization of $11.64 billion and generates $482.25 million in revenue each year. The biotechnology company earns $-125,530,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis. Seattle Genetics employs 1,100 workers across the globe.
How can I contact Seattle Genetics?
Seattle Genetics' mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The biotechnology company can be reached via phone at 425-527-4000 or via email at [email protected]
MarketBeat Community Rating for Seattle Genetics (NASDAQ SGEN)
MarketBeat's community ratings are surveys of what our community members think about Seattle Genetics and other stocks. Vote "Outperform" if you believe SGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
